NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free GOVX Stock Alerts $1.42 -0.05 (-3.40%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.40▼$1.6350-Day Range$1.42▼$2.7152-Week Range$1.40▼$11.54Volume37,455 shsAverage Volume26,552 shsMarket Capitalization$3.28 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get GeoVax Labs alerts: Email Address GeoVax Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8,350.7% Upside$120.00 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1,118 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeoVax Labs has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.28% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 4.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GOVX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,118.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About GeoVax Labs Stock (NASDAQ:GOVX)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVX Stock News HeadlinesApril 17, 2024 | americanbankingnews.comGeoVax Labs (NASDAQ:GOVX) Stock Price Down 4.8%April 5, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineApril 27, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. March 28, 2024 | globenewswire.comGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressMarch 22, 2024 | investing.comGeoVax Labs Inc (GOVX)March 12, 2024 | globenewswire.comGeoVax to Present at the 36th Annual Roth ConferenceMarch 6, 2024 | globenewswire.comGeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing SystemMarch 2, 2024 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call TranscriptApril 27, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 1, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comGeoVax Reports 2023 Year-End Financial Results and Provides Business UpdateFebruary 28, 2024 | benzinga.comEarnings Outlook For Geovax LabsFebruary 24, 2024 | msn.comGeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78February 23, 2024 | msn.comInMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are BuyingFebruary 22, 2024 | finance.yahoo.comGeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024February 22, 2024 | globenewswire.comGeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024February 20, 2024 | finance.yahoo.comGeoVax Labs, Inc. (GOVX)February 20, 2024 | uk.finance.yahoo.comGeoVax to Present at the 2024 BIO CEO & Investor ConferenceFebruary 19, 2024 | finance.yahoo.comGeoVax to Present at the 2024 BIO CEO & Investor ConferenceFebruary 19, 2024 | globenewswire.comGeoVax to Present at the 2024 BIO CEO & Investor ConferenceJanuary 29, 2024 | msn.comGeoVax Labs to effect 1-for-15 reverse stock split to regain compliance with Nasdaq ruleJanuary 8, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologyJanuary 8, 2024 | finance.yahoo.comGeoVax Appoints Dr. Marc Pipas as Executive Medical Director, OncologyNovember 30, 2023 | finance.yahoo.comGeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine CongressNovember 29, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming December Investor EventsNovember 28, 2023 | finance.yahoo.comGeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine CongressNovember 27, 2023 | msn.comGeovax Labs (GOVX) Price Target Increased by 12.50% to 6.12See More Headlines Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/23/2023Today4/27/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GOVX CUSIPN/A CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$120.00 High Stock Price Target$120.00 Low Stock Price Target$120.00 Potential Upside/Downside+8,350.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($13.3434) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-189.16% Return on Assets-140.10% Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio2.24 Sales & Book Value Annual Sales$80,000.00 Price / Sales41.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.44Miscellaneous Outstanding Shares2,310,000Free Float2,216,000Market Cap$3.28 million OptionableNot Optionable Beta2.89 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 74)Chairman, President & CEO Comp: $384.2kDr. Mark J. Newman Ph.D. (Age 69)Chief Scientific Officer Comp: $291.5kDr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Comp: $361.03kDr. Harriet Latham Robinson Ph.D. (Age 86)Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board Mr. Thomas O'BrienVice President of Quality Systems & ComplianceMr. Jeffrey WelchHead of Process Development & Manufacturing OperationsDr. Valerie C. Montgomery Rice FACOG (Age 61)M.D., Special Advisor to the Chairman & CEO and Board of Directors Mr. John NilesHead of Commercial OperationsDr. John W. Sharkey Ph.D. (Age 68)Vice President of Business Development More ExecutivesKey CompetitorsPhaseBio PharmaceuticalsNASDAQ:PHASVirpax PharmaceuticalsNASDAQ:VRPXMustang BioNASDAQ:MBIORevelation BiosciencesNASDAQ:REVBEvoke PharmaNASDAQ:EVOKView All CompetitorsInsiders & InstitutionsDavid A DoddBought 520 shares on 2/21/2024Total: $1,118.00 ($2.15/share)Armistice Capital LLCBought 1,626,516 shares on 2/13/2024Ownership: 91.377%Kelly T Jr. MckeeBought 462 shares on 12/22/2023Total: $2,494.80 ($5.40/share)Kelly T Jr. MckeeBought 643 shares on 9/25/2023Total: $5,015.40 ($7.80/share)David A DoddBought 2,339 shares on 8/25/2023Total: $19,998.45 ($8.55/share)View All Insider TransactionsView All Institutional Transactions GOVX Stock Analysis - Frequently Asked Questions Should I buy or sell GeoVax Labs stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GOVX shares. View GOVX analyst ratings or view top-rated stocks. What is GeoVax Labs' stock price target for 2024? 1 equities research analysts have issued 1 year target prices for GeoVax Labs' shares. Their GOVX share price targets range from $120.00 to $120.00. On average, they anticipate the company's stock price to reach $120.00 in the next twelve months. This suggests a possible upside of 8,350.7% from the stock's current price. View analysts price targets for GOVX or view top-rated stocks among Wall Street analysts. How have GOVX shares performed in 2024? GeoVax Labs' stock was trading at $5.4150 at the beginning of the year. Since then, GOVX stock has decreased by 73.8% and is now trading at $1.42. View the best growth stocks for 2024 here. Are investors shorting GeoVax Labs? GeoVax Labs saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 6,600 shares, a decline of 60.2% from the March 15th total of 16,600 shares. Based on an average trading volume of 40,100 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the shares of the company are short sold. View GeoVax Labs' Short Interest. When is GeoVax Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GOVX earnings forecast. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) issued its quarterly earnings data on Thursday, March, 23rd. The company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by $0.45. During the same period in the previous year, the business earned ($33.60) earnings per share. When did GeoVax Labs' stock split? Shares of GeoVax Labs reverse split on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOVX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
